Hiroshi Hongo

Hiroshi Hongo

Auto-generated profile, based on publicly available information

Hiroshi Hongo

Department of Urology Keio University School of Medicine Tokyo Japan

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2019 in Clinical Genitourinary Cancer
Verified
Journal Article
Closed access
KWKeitaro Watanabe
Keitaro Watanabe
TKTakeo Kosaka
Takeo Kosaka
EAEriko Aimono
Eriko Aimono
HHHiroshi Hongo
Hiroshi Hongo
SMShuji Mikami
Shuji Mikami
MOMototsugu Oya
Mototsugu Oya

21 December 2023 in PNAS Nexus
Verified
Journal Article
Open access
PDF file
HHHiroshi Hongo
Hiroshi Hongo
TKTakeo Kosaka
Takeo Kosaka
KTKen-ichi Takayama
Ken-ichi Takayama
YBYuto Baba
Yuto Baba
YYYota Yasumizu
Yota Yasumizu
MOMototsugu Oya
Mototsugu Oya
Although the treatment armamentarium for patients with metastatic prostate cancer has improved recently, treatment options after progression on cabazitaxel (CBZ) are limited. To identify the mechanisms underlying CBZ resistance and therapeutic targets, we performed single-cell RNA sequencing of circulating tumor cells (CTCs) from patients with CBZ-resistant prostate cancer. Cells were clustered based on gene expression profiles. In silico screening was used to nominate candidate drugs for overcoming CBZ resistance in castration-resistant prostate cancer. CTCs were divided into three to four clusters, reflecting intrapatient tumor heterogeneity in refractory prostate cancer. Pathway analysis revealed that clusters in two cases showed up-regulation of the oxytocin (OXT) receptor–signaling pathway. Spatial gene expression analysis of CBZ-resistant prostate cancer tissues confirmed the heterogeneous expression of OXT-signaling molecules. Cloperastine (CLO) had significant antitumor activity against CBZ-resistant prostate cancer cells. Mass spectrometric phosphoproteome analysis revealed the suppression of OXT signaling specific to CBZ-resistant models. These results support the potential of CLO as a candidate drug for overcoming CBZ-resistant prostate cancer via the inhibition of OXT signaling.

26 September 2024 in Cancer Science
Verified
Journal Article
Open access
TTTomoki Takei
Tomoki Takei
YHYuki Hamamura
Yuki Hamamura
HHHiroshi Hongo
Hiroshi Hongo
ETEtsu Tashiro
Etsu Tashiro
MIMasaya Imoto
Masaya Imoto
MOMototsugu Oya
Mototsugu Oya
Prostate cancer is initially androgen‐dependent but often relapses to an androgen‐independent state called castration‐resistant prostate cancer (CRPC). Currently approved therapies have limited efficacy against CRPC, highlighting the need for novel therapeutic strategies. To address this need, we conducted a drug screen in our previously established aggressive CRPC cell model. We found that formycin A induced cell death in CRPC model cells but not in parental prostate cancer cells. In addition, formycin A upregulated death receptor 5 through the induction of endoplasmic reticulum stress, activating the “extrinsic” apoptosis pathway in CRPC model cells. Moreover, formycin A showed in vivo antitumor efficacy against CRPC xenografts in castrated nude mice. Thus, our findings highlight the potential of formycin A as a CRPC therapeutic.

10 February 2014 in Canadian Urological Association Journal
Verified
Journal Article
Open access
PDF file
NNNaoya Niwa
Naoya Niwa
NTNobuyuki Tanaka
Nobuyuki Tanaka
MHMinoru Horinaga
Minoru Horinaga
HHHiroshi Hongo
Hiroshi Hongo
YIYujiro Ito
Yujiro Ito
TWTakuro Watanabe
Takuro Watanabe
Primary renal lymphoma is rare, and most are intermediate- and high-grade lymphomas of B-cell lineage, such as diffuse large B-cellor Burkitt lymphoma. We report a case of low-grade B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT) arising from the kidney. Only a few cases of primary renal MALT lymphoma have been published.